Literature DB >> 6415171

A unique DR-related B cell differentiation antigen.

M A Shipp, B D Schwartz, C C Kannapell, R C Griffith, M G Scott, P Ahmed, J M Davie, M H Nahm.   

Abstract

The Ia or class II molecules in both mouse and man are the basis for the genetic control of the immune response. In addition to DR, other class II antigens have been described in man. We describe a new human Ia antigen K19, recognized by three monoclonal antibodies (HK-9, HK-19, and HK-20). This antigen has the general biochemical characteristics of an Ia antigen but is different from a DR antigen. Further, this antigen is found only on mature B lymphocytes and not on monocytes and activated T cells. Thus, this antigen may represent a new Ia-like molecule that is preferentially expressed on mature B cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Characterization of two distinct antigens expressed on either resting or activated human B cells as defined by monoclonal antibodies.

Authors:  Y Kokai; Y Ishii; K Kikuchi
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  HLA-DQw3.2 allele of the DR4 haplotype is associated with insulin-dependent diabetes; correlation between DQ beta restriction fragments and DQ beta chain variation.

Authors:  D S Monos; R S Spielman; K J Gogolin; S F Radka; L Baker; C M Zmijewski; M Kamoun
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies.

Authors:  Y Ishii; T Takami; H Yuasa; T Takei; K Kikuchi
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

4.  L cells expressing DQ molecules of the DR3 and DR4 haplotypes: reactivity patterns with mAbs.

Authors:  D S Monos; E Czanky; S J Ono; S F Radka; D Kappes; J L Strominger
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.

Authors:  Rekha Raghunathan; Swetha Mahesula; Kranthi Kancharla; Preethi Janardhanan; Yeshwant L A Jadhav; Robert Nadeau; German P Villa; Robert L Cook; Colleen M Witt; Jonathan A L Gelfond; Thomas G Forsthuber; William E Haskins
Journal:  Part Part Syst Charact       Date:  2013-04       Impact factor: 3.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.